Table 1.
Citation | Preference assessment method | Preference content | Respondent (N) | Key results |
---|---|---|---|---|
Efron et al46 | Single-item assessment of preference at end of treatment period in a crossover trial (no further details provided) | Children received treatment with MPH and DEX, each for 2 weeks in a double-blind, crossover trial. After both treatment periods, parents were asked to specify which treatment they preferred | Parents of children (mean age of 8.73 years) with ADHD (N = 125) | 46 of 104 parents (36.8%) indicated that they preferred the DEX treatment period, and 58 parents (46.4%) indicated that they preferred the MPH treatment period |
Fredericks and Kollins49 | Double-blind choice procedure | Participants received double-blind treatment with either placebo or MPH during four study ‘sampling sessions’. During eight subsequent ‘choice sessions’, participants chose which treatment they would receive: placebo, MPH, or neither | Adults with ADHD (N = 10) | MPH was preferred in 50% of the choices; placebo 32.5%, neither 17.5% (significant difference among choices; χ2 = 52.5, P < 0.001) |
MacDonald Fredericks and Kollins50 | Double-blind choice procedure | Participants received double-blind treatment with either placebo or MPH during six study ‘sampling sessions’. During six subsequent ‘choice sessions’, participants chose which treatment they would receive: placebo, MPH, or neither | Children/adolescents (aged 10–14) with ADHD (N = 5) | MPH was preferred in 60% of the choices; placebo 20%; neither 20% (significant difference among choices; χ2 = 9.6, P < 0.01) |
Pelham et al48 | Unspecified preference assessment completed at end of double-blind, placebo-controlled, clinical trial | Children received treatment with placebo, IR MPH (three times daily), and a once daily MPH formulation in a randomly selected order. At the end of the three 7-day treatment periods, parents were asked to choose which of the treatment weeks they preferred for their child | Parents of children with ADHD (aged 6–12) (N = 68) | 47% of the parents selected once daily MPH as the treatment of choice, 31% selected IR MPH, 15% chose their child’s previous MPH treatment, and 7% either chose placebo or had no preference |
Quintana et al47 | Unspecified preference assessment completed at end of clinical trial | In this 6-week study, children and adolescents with incomplete response or intolerance to stimulant treatment switched to atomoxetine after the first week. The two treatments were compared using an unspecified preference assessment method | Children and adolescents (aged 6–17 years) with ADHD (N = 58) | 65.5% of subjects reported a preference for atomoxetine treatment over their previous psychostimulant |
Abbreviations: MPH, methylphenidate; DEX, dexamphetamine; ADHD, attention-deficit/hyperactivity disorder; IR, immediate release.